COLCRYS Resources

Gout pain strikes hard, fast, and at any time, especially at night1

Acute gout attacks peak within 12 hours and can last over a week (3‑14 days)1–3

Gout attack pain is so intense that even the weight of a bedsheet can be excruciating
  • Patients are more than twice as likely to suffer a gout attack at nighttime (midnight-8 am) vs daytime (8 am-4 pm)4
  • Half of all gout patients have ≥3 attacks per year5
Martin, patient quote
COLCRYS (colchicine, USP) clinical data

Help reduce gout attack pain at 24 hours6,7

Taken at the first sign, COLCRYS reduced the pain of acute gout attacks.

See the data
Learn about recommendations and mechanism of action for COLCRYS (colchicine, USP)

Be there with COLCRYS

Learn about recommendations and mechanism of action.

Find out now

Important Safety Information

See More See Less
  • COLCRYS is contraindicated in patients with renal or hepatic impairment who are currently prescribed P-gp inhibitors or strong inhibitors of CYP3A4. In these patients, life-threatening and fatal colchicine toxicity has been reported with colchicine taken in therapeutic doses. Dose adjustments of COLCRYS may be required when co-administered with P-gp or CYP3A4 inhibitors in
  • COLCRYS is contraindicated in patients with renal or hepatic impairment who are currently prescribed P-gp inhibitors or strong inhibitors of CYP3A4. In these patients, life-threatening and fatal colchicine toxicity has been reported with colchicine taken in therapeutic doses. Dose adjustments of COLCRYS may be required when co-administered with P-gp or CYP3A4 inhibitors in patients with normal renal and hepatic function.
  • Fatal overdoses, both accidental and intentional, have been reported in adults and children who have ingested colchicine. Keep COLCRYS out of the reach of children.
  • Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, and aplastic anemia have been reported in patients taking colchicine at therapeutic doses.
  • Colchicine-induced neuromuscular toxicity and rhabdomyolysis have been reported with chronic treatment in therapeutic doses, especially when colchicine is prescribed in combination with other drugs known to cause this effect. Patients with renal dysfunction and elderly patients, even those with normal renal and hepatic function, are at increased risk.
  • Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine.
  • The most common adverse reactions in clinical trials were diarrhea (23%) and pharyngolaryngeal pain (3%).

Indications

COLCRYS (colchicine, USP) 0.6 mg tablets are indicated in adults for the prophylaxis of gout flares and treatment of acute gout flares when taken at the first sign of a flare.

COLCRYS is not an analgesic medication and should not be used to treat pain from other causes.

Please see the complete Prescribing Information and Medication Guide.

Show references Hide references
  1. Burns CM, Wortmann RL. Clinical features and treatment of gout. In: Firestein GS, Budd RC, Gabriel SE, McInnes IB, O'Dell JR, eds. Kelley's and Firestein's Textbook of Rheumatology. Vol 2. 10th ed. Philadelphia, PA: Saunders Elsevier; 2017:1620-1644
  2. Neogi T, Jansen TL, Dalbeth N, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74(10):1789-1798.
  3. Edwards NL. Clinical gout. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, eds. Rheumatology. Vol 1. 6th ed. Philadelphia, PA: Elsevier Mosby; 2015:1569-1574.
  4. Choi HK, Niu J, Neogi T, et al. Nocturnal risk of gout attacks. Arthritis Rheumatol. 2015;67(2):555-562.
  5. Hirsch JD, Terkeltaub R, Khanna D, et al. Gout disease-specific quality of life and the association with gout characteristics. Patient Relat Outcome Meas. 2010;1:1-8.
  6. COLCRYS (colchicine, USP) prescribing information. Takeda Pharmaceuticals.
  7. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty-four–hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62(4):1060-1068.

COLCRYS is a trademark of Takeda Pharmaceuticals U.S.A., Inc., registered with the U.S. Patent and Trademark Office and used under license by Takeda Pharmaceuticals America, Inc.

©2018 Takeda Pharmaceuticals U.S.A., Inc.
This site is intended for use by U.S. residents only.